H.C. Wainwright assumed coverage of Iterum Therapeutics (ITRM) with a Buy rating and $9 price target Iterum is a pre-commercial stage company with an FDA approved product, the analyst tells investors in a research note. The firm says the company has the potential to deliver in urinary tract infections and infectious disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM: